Chronic News and Research

RSS

Novel scaffold protein regulates mu opioid receptor induced signaling activation

Researchers found initial confirmation that a novel scaffold protein previously unassociated with the mu opioid receptor (MOR) regulates MOR-induced signaling activation.

4 Mar 2014

Blocking Netrin-1 in immune system stops chronic inflammation and insulin resistance tied to obesity

Researchers at NYU Langone Medical Center have found that blocking the action of a key signaling molecule in the immune system known as Netrin-1 stalls chronic inflammation and insulin resistance tied to obesity and often derived from fatty diets.

4 Mar 2014

Outbursts of anger may trigger heart attacks and strokes, shows study

Outbursts of anger may trigger heart attacks, strokes and other cardiovascular problems in the two hours immediately afterwards, according to the first study to systematically evaluate previous research into the link between the extreme emotion and all cardiovascular outcomes.

4 Mar 2014

Research suggests that MBSR program can reduce employee stress and burnout

Within the health care industry and beyond, daily exposure to stress can lead to negative consequences for employees both on and off the job - from apathy and burnout to physical illness or mental impairments.

4 Mar 2014

Drug that blocks LTA4 hydrolase enzyme plays key role in body's inflammatory response

There have been great expectations regarding the production of a drug to block the enzyme LTA4 hydrolase, which plays a key role in the body's inflammatory response.

4 Mar 2014

Study finds significant reduction in hospital admissions with Medicare Part D prescription coverage

A new study by the Johns Hopkins Bloomberg School of Public Health and the University of Illinois at Chicago finds that Medicare Part D prescription coverage significantly reduced hospital admissions and program expenditures totaling $1.5 billion annually.

4 Mar 2014

UT Southwestern Medical Center opens new Texas Institute for Brain Injury and Repair

UT Southwestern Medical Center today launched the new Texas Institute for Brain Injury and Repair, a state-funded initiative to promote innovative research and education, with the goals of accelerating translation into better diagnosis and revolutionizing care for millions of people who suffer brain injuries each year.

4 Mar 2014

AbbVie's PEARL-III study meets primary, secondary endpoints in patients with chronic GT1b HCV infection

The first detailed results from AbbVie's pivotal phase III study, PEARL-III, were presented today as part of the 21st Conference on Retroviruses and Opportunistic Infections (CROI) press conference and will also be presented as a late-breaker at the conference on March 4.

4 Mar 2014

Experts recommend several steps to improve care for prisoners

The very premise of prison invites members of society to think of the people there as walled-off and removed. But more than 95 percent of prisoners will return to the community, often carrying significant health burdens and associated costs with them. In an article in the March issue of the journal Health Affairs, several experts who participated in a scientific workshop convened by the National Research Council and the Institute of Medicine recommend several steps and ideas consistent with health reform to improve care for prisoners while they are incarcerated and after they return to society.

4 Mar 2014

New research uncovers abnormal molecular signaling pathways for kidney failure

Prevention and reversal of chronic kidney disease is an urgent public health need. The disease affects 1 in 10 Americans, is debilitating and deadly, and existing drugs, at best, offer only mild delay in progression to end-stage kidney failure.

4 Mar 2014

Arrowhead receives approval to initiate Phase 2a clinical trial of ARC-520 for chronic HBV infection

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it received regulatory approval to begin a Phase 2a clinical trial of ARC-520, its RNAi-based drug candidate for the treatment of chronic hepatitis B virus (HBV) infection.

4 Mar 2014

OPKO Health consolidated revenues increase about 30% to $20.7 million in Q4 2013

OPKO Health, Inc., a multi-national biopharmaceutical and diagnostics company, today reported operating and financial results for its 2013 fourth quarter and full year ended December 31, 2013.

4 Mar 2014

Researchers examine how ACA could affect Americans living with HIV/AIDS

A series of papers in the March issue of Health Affairs examines how the Affordable Care Act could affect two sectors of the most vulnerable Americans - those living with HIV/AIDS and people who have recently cycled through jail.

4 Mar 2014

Insurers gather new customers' health information -- a critical step in calculating prices for next year's plans offered on exchanges

Meanwhile, Reuters reports that chronically ill consumers who obtain coverage from the online insurance marketplaces may still face high drug costs despite the health law's ban on discriminatory insurance practices. Also, news outlets report on Time magazine's cover story that details how the Obama administration almost shutdown healthcare.gov during its early, fitful days.

3 Mar 2014

Photoreactive compounds open new routes to treatment of neurological diseases

Photoreactive compounds developed by scientists of Ludwig-Maximilians-Universitaet (LMU) in Munich directly modulate nerve-cell function, and open new routes to the treatment of neurological diseases, including chronic pain and certain types of visual impairment.

3 Mar 2014

People with learning disabilities have lower life expectancy, suffer physical disabilities, chronic conditions

People with learning (intellectual) disabilities have a lower life expectancy than the general population and are more likely to suffer physical disabilities and chronic conditions.

3 Mar 2014

Cell Therapeutics initiates Phase 3 clinical trial to evaluate pacritinib in patients with myelofibrosis

Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced the initiation of a Phase 3 clinical trial, known as PERSIST-2, which will evaluate pacritinib, a novel, investigational JAK2/FLT3 inhibitor, in patients with myelofibrosis whose platelet counts are less than or equal to 100,000 per microliter (uL).

3 Mar 2014

New study may open door to better diagnosis, treatment for chronic insomnia

Johns Hopkins researchers report that people with chronic insomnia show more plasticity and activity than good sleepers in the part of the brain that controls movement.

3 Mar 2014

Researchers make new advances in study of chronic lymphatic leukaemia genome

A study led by Dr. Roderic Guig- from the Centre for Genomic Regulation in Barcelona, as part of the Chronic Lymphatic Leukaemia Genome Consortium, has made new advances in the study of this disease.

3 Mar 2014

Study: College athletes often struggle to stay active in later years

An Indiana University study found that elite college athletes -- typically the picture of health and vitality -- often struggle to stay active in later years, facing limitations to their day-to-day activities in middle age that could be a result of injuries during their athletic career.

3 Mar 2014

Chronic News and Research

Novel scaffold protein regulates mu opioid receptor induced signaling activation

Blocking Netrin-1 in immune system stops chronic inflammation and insulin resistance tied to obesity

Outbursts of anger may trigger heart attacks and strokes, shows study

Research suggests that MBSR program can reduce employee stress and burnout

Drug that blocks LTA4 hydrolase enzyme plays key role in body's inflammatory response

Study finds significant reduction in hospital admissions with Medicare Part D prescription coverage

UT Southwestern Medical Center opens new Texas Institute for Brain Injury and Repair

AbbVie's PEARL-III study meets primary, secondary endpoints in patients with chronic GT1b HCV infection

Experts recommend several steps to improve care for prisoners

New research uncovers abnormal molecular signaling pathways for kidney failure

Arrowhead receives approval to initiate Phase 2a clinical trial of ARC-520 for chronic HBV infection

OPKO Health consolidated revenues increase about 30% to $20.7 million in Q4 2013

Researchers examine how ACA could affect Americans living with HIV/AIDS

Insurers gather new customers' health information -- a critical step in calculating prices for next year's plans offered on exchanges

Photoreactive compounds open new routes to treatment of neurological diseases

People with learning disabilities have lower life expectancy, suffer physical disabilities, chronic conditions

Cell Therapeutics initiates Phase 3 clinical trial to evaluate pacritinib in patients with myelofibrosis

New study may open door to better diagnosis, treatment for chronic insomnia

Researchers make new advances in study of chronic lymphatic leukaemia genome

Study: College athletes often struggle to stay active in later years

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Latest News